Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Barinthus Biotherapeutics (BRNS) Change in Receivables (2020 - 2023)

Barinthus Biotherapeutics (BRNS) has disclosed Change in Receivables for 4 consecutive years, with -$194000.0 as the latest value for Q3 2023.

  • For the quarter ending Q3 2023, Change in Receivables rose 98.21% year-over-year to -$194000.0, compared with a TTM value of -$194000.0 through Jun 2024, up 98.85%, and an annual FY2023 reading of -$5.8 million, down 199.43% over the prior year.
  • Change in Receivables was -$194000.0 for Q3 2023 at Barinthus Biotherapeutics, up from -$645000.0 in the prior quarter.
  • Across five years, Change in Receivables topped out at $18.4 million in Q1 2022 and bottomed at -$10.9 million in Q3 2022.
  • Average Change in Receivables over 4 years is -$67000.0, with a median of -$284000.0 recorded in 2021.
  • Peak annual rise in Change in Receivables hit 8923.08% in 2022, while the deepest fall reached 181200.0% in 2022.
  • Year by year, Change in Receivables stood at $448000.0 in 2020, then crashed by 116.29% to -$73000.0 in 2021, then crashed by 350.68% to -$329000.0 in 2022, then soared by 41.03% to -$194000.0 in 2023.
  • Business Quant data shows Change in Receivables for BRNS at -$194000.0 in Q3 2023, -$645000.0 in Q2 2023, and -$5.0 million in Q1 2023.